Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive tumors, with a low rate of survival, likely due to the tendency of the tumor for early local and distant spread. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. Surgical resection still represents the best curative treatment for PDAC, although only 10-20% of patients are upfront resectable at diagnosis, 50% has metastatic disease and 35% locally advanced cancer. The 5-year overall survival (OS) after curative resection is limited to 20%. Moreover among patients who undergo surgery, 30% develop early recurrence while most of them will eventually relapse. The risk of early failure after surgery could be associated with inadequate preoperative radiological staging, lack of radical surgery and differences in tumor aggressiveness. In recent years, more accurate patient categorization due to sophisticated imaging tools and techniques increase the survival rate while neoadjuvant treatment can help surgeons select patients who will benefit most from surgery. Neoadjuvant therapy includes chemotherapy alone, chemoradiotherapy, chemotherapy with chemoradiation and targeted therapies. The aim of this review is to present the available data concerning the management of patients with borderline PDAC. (Ann Hepatobiliary Pancreat Surg 2019;23:97-108)
INTRODUCTION
Borderline resectable PDAC in the pancreatic body/tail is the solid tumor contact with the CA of ＜180° or contact with CA＞180° without involvement of the aorta and gastroduodenal artery in order to allow a modified Appleby surgery. The above vessel involvement is under discussion because some members of NCCN believe that it is contraindication for resection. 3 Unresectable ductal adenocarcinoma regarded the tumor with distant metastasis, including non-regional lymph node metastasis. Depended of the anatomy, PDAC is considered unresectable if it is in contact with SMA or CA more than 180° or has any aortic and venous involvement which cannot be reconstructed surgically. 3 There is always a risk of early failure after surgery which commonly associated with inadequate preoperative radiological staging, lack of radical surgery and variation in tumor aggressiveness. Recent studies indicate that PDAC appears a heterogeneous spectrum of different biological characteristics which determine tumor progression and its response to treatment. 4 
PANCREATIC CANCER BIOLOGY
Despite recent progress in treatment of pancreatic cancer, the overall median survival still remains extremely poor, As a result, new curative approaches are urgently needed to be applied. 5 Remarkably, due to self-sufficiency in growth signals, limitless replication, apoptosis resistance and metastatic invasion, pancreatic tumor cells have decreased response to conventional radio-and chemotherapy. 5, 6 Therefore, substantial research into tumor microenvironment is required to identify targets for developing potential treatment agents. 6 TGF- seems to be a potential biomarker of tumor activity, as it regulates the epithelial-mesenchymal transition process. 6 Melisi et al. 7 demonstrated a phase II study comparing the efficacy of galunisertib, a TGF- inhibitor, and gemcitabine in contrast to gemcitabine alone in patients with unresectable pancreatic cancer. Combination of agents resulted in a higher median overall survival of 10.9
months, compared with 7.2 months for gemcitabine alone, thus leading to tumor suppression, when decreased levels of TGF- were noted. 7 Overexpression of vascular endothelial growth factor (VEGF) in pancreatic cancer promotes neo-angiogenesis and disorganization of tumor vasculature. 6 In a double-blind, placebo-controlled, phase III trial, axitinib, a selective inhibitor of VEGF receptors, and gemcitabine, have been administered in patients with locally advanced or metastatic pancreatic cancer. 8 However, the addition of axitinib to gemcitabine compared to gemcitabine and placebo showed no significant improvement in overall survival. 8 Recent studies have also focused on therapeutic agents targeting stroma cells. Pancreatic stellate cells (PSCs), also known as activated fibroblasts, play a central role in pancreatic tumor resistance, invasion and progression increasing extracellular matrix synthesis. 9 All-trans retinoic acid (ATRA), combined with gemcitabine, can diminish PSCs' invasive ability through the RAR-/MLC-2 pathway, thereby resulting in a more quiescent phenotype. 10 In addition, paresotide, a somatostatin analogue, combined with gemcitabine, was effectively utilized to inhibit the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts, reducing tumor growth and chemore- 
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND PLATELET TO LYMPHOCYTE RATIO (PLR)
Prognostic markers for risk stratification in patients with borderline pancreatic cancer would be of significant value to clinicians, especially for those with economical and easily calculated features. Such markers include C-reactive protein (CRP), the Modified Glasgow Prognostic Score, and ratios such as the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). 14, 15 NLR in specific has been thoroughly investigated in other cancers and its predictive importance has been reported in cases such as colorectal cancer and colorectal liver metastases. [16] [17] [18] Proposed mechanisms for the role of NLR include relative lymphocytopenia resulting in a poorer immune response to malignancy and a high neutrophil count enhancing the development of a neoplasmatic tumor through the release of vascular endothelial growth factor. [16] [17] [18] Similarly PLR has been reported to hold a significant predictive value in regards to overall survival (OS) in ovarian cancer, colorectal cancer and also colorectal liver metastases. [19] [20] [21] [22] In regards to borderline and locally advanced pancreatic cancer, Lee et al. 23 Previously Hasegawa et al. 24 had investigated a cohort of pancreatic cancer patients receiving neoadjuvant chemoradiotherapy prior to complete surgical resection, and reported that a pre treatment NLR was an independent predictive marker of the pathological response to preoperative therapy. Asari et al. 25 also reported, in a cohort of borderline pancreatic cancer (BR-PDAC) patients undergoing curative resection upfront, a preoperative NLR＞3
to be an independent predictive risk factor. The authors also showed that elevated preoperative NLR and PLR values had a prognostic role regarding overall survival in BR-PDAC patients.
CHEMOTHERAPY
Neoadjuvant treatment has been increasingly applied in patients with borderline resectable pancreatic cancer, as it ensures the delivery of multidisciplinary management to all patients who are about to undergo surgery, downstages tumors to facilitate surgical resection and also increases total and R0 resection rates. 26, 27 Current clinical trials and meta-analyses have been comparing the efficacy of the main cytotoxic agents used in neoadjuvant chemotherapy, 26 as well as the role of radiotherapy (RT), currently used as chemoradiotherapy (cXRT) in the management of borderline resectable pancreatic cancer. 28 Dhir et al. 29 completed a systematic meta-analysis on the 32 However, a recent study of 575 patients with locally advanced pancreatic cancer revealed that FOLFIRINOX chemotherapy resulted in significantly higher secondary resection rates and overall survival compared to gemcitabine-based cXRT. Overall negative resection rate was 33%; with 55% of borderline resectable and 10% of unresectable patients achieving R0 resection margins. 34 FOLFIRINOX was also found to be more cytotoxic agent compared with gemcitabine for patients with metastatic pancreatic tumors. 35 Conroy et al. 35 reported a study of 342 metastatic patients, treated with FOLFIRINOX or gemcitabine for six months.
Pooled estimates showed that the response rate in the Besides FOLFIRINOX, gemcitabine/nab-paclitaxel/S-1 (GAS) has also administered as combination neoadjuvant treatment in patients with borderline resectable pancreatic cancer. 27 A phase I study of the above mentioned chemotherapy agents has been published from Kondo et al. 36 in 37 Observing the effectiveness of mFOLFIRINOX in adjuvant treatment, Dr. Conroy indicated that it could be also successfully utilized as a neoadjuvant therapy regiment for patients with metastatic pancreatic cancer and appear more effective than gemcitabine, which is the current standard of treatment (Table   1) . 37 
RADIATION THERAPY
Although novel agents, such as FOLFIRINOX and nab-paclitaxel, have been added to neoadjuvant treatment sequencing for pancreatic cancer, challenges still exist in improving survival outcomes and disease local control. 38 The LAP07 randomized clinical trial proved that the addition of conventionally chemoradiotherapy to chemotherapy did not improve the overall survival in locally advanced pancreatic cancer or reduce treatment toxicity. 39 In a recent meta-analysis of 41 prospective studies, Chang et al. 40 also evaluated the role of consolidation chemoradiotherapy (CCRT) followed by chemotherapy in locally advanced pancreatic cancer. CCRT utilized in a total of 1018 patients, while chemotherapy alone in 954 patients.
No significant difference was noted between 1-year survival benefit with the administration of CCRT after induction chemotherapy in comparison to chemotherapy alone. 40 As a result, current studies aim to assess the benefit of different techniques and modalities of radiotherapy in combination with systemic therapies. 38, 41 A randomized phase II ESPAC-5F trial is already about to assess the effectiveness and safety of chemoradiotherapy with gemcitabine or capecitabine following gemcitabine plus capecitabine chemotherapy in patients with locally advanced pancreatic cancer. If encouraging, this trial will determine the experimental arm of a phase III study comparing radiation therapy against chemotherapy alone. Stereotactic body radiation therapy (SBRT) is an emerging approach which enables the delivery of higher doses of radiation to the tumor, with minimal doses to the adjacent normal tissues. 38 In contrast with conventionally fractionated radiotherapy (CFRT), where the duration of systemic treatment is up to 6 weeks, patients treated with SBRT need to be off systemic therapy for a short period of time, typically one to two weeks, as it employs a hypofractionated regiment. 41 In a retrospective review of 8,450 patients with locally advanced pancreatic cancer using the National Cancer Database, receipt of SBRT leaded to higher rates of median overall survival (13.9 months vs 11.6 months) and 2-year overall survival (21.7% vs 16.5%) in comparison with CFRT. 42 Furthermore, pooled results from current literature proved that tumor local control was almost 80% after one year treatment with SBRT. 41 Gastrointestinal toxicity rates caused by higher doses of SBRT could be eliminated with the utilization of stereotactic MRIguided radiotherapy (SMART), allowing SBRT to achieve high doses of hypofractionated radiation without damaging surrounding radiosensitive normal structures. 38 Intensity-modulated radiation therapy (IMRT) is also an irradiation therapy which achieves an increase in target tumor dose, while minimizing toxicity to surrounding normal tissues. 43 Masui et al. 43 investigated the advantages of IMRT over conventional RT for patients with borderline resectable pancreatic cancer with arterial abutment. A total of 29 patients were enrolled in the study; 18 of them underwent IMRT, while 12 of them conventional RT before resection. R0 resection rates were 84% for the patients treated with IMRT and 83% for the RT group.
Local control rate, according to the Evans classification, was higher in the IMRT group than in the RT group, while median overall survival was 32 months and 13.8 months respectively. 43 Several recent studies have proved that the utilization of IMRT in locally advanced pancreatic cancer leaded to excellent local control and survival rates. 44 In addition, Goto et al. 44 implemented dynamic tumor-tracking IMRT (DTT-IMRT) with real-time monitoring, using a gimbal mounted linac, in patients with locally advanced pancreatic tumors, so as to manage tumor motion and avoid deviation between planned and actual dose distribution. In a follow-up period of 22.9 months, median overall survival was estimated at 23.6 months and locoregional progression free survival rates were 90.9% and 37.9% after one and two years respectively, while severe gastrointestinal toxicity was noted in only one patient, compared to the outcomes of the previously mentioned LAP07 clinical trial, where the median survival was 15.2 months and grade 3-4 toxicity rates were 23.1%.
44,39
Last but not least, particle therapy, including proton and carbon ion therapy, is being explored as a novel treatment modality for pancreatic cancer, providing greater biological effectiveness because of a higher linear energy transfer compared to photon treatment, thereby decreasing 46 2018 Carbon ion therapy in combination with gemcitabine 21.5 -dose to adjacent tissues within the exit beam path. 41 In a dosimetric trial comparing particle therapy and IMRT, 13 patients with unresectable cancer of the pancreatic head were treated with proton plans calculated to 55 Gy in 25 fractions. 45 Proton therapy minimized stomach, duodenum and small bowel dose in the mid to low dose regions compared to IMRT, but it failed to derive reduced dose in the mid to high dose regions, as well. 45 Further follow-up is needed to define the biological significance of decreased dose to the low dose regions. In another multi-institutional study, 72 patients with locally advanced pancreatic cancer were treated with carbon ion therapy in combination with precedent or concurrent gemcitabine. 46 Median overall survival was 21.5 months (95% CI: 11.8-31.2 months), while concurrent chemotherapy and the higher prescribed dose of radiation were statistically significant factors regarding overall survival. 46 In total, new radiotherapy modalities are an encouraging approach for the treatment of non-resectable pancreatic cancer, alone or in combination with systemic chemotherapy (Table 2) .
IMMUNOTHERAPIES IN PANCREATIC CANCER
Immunotherapy against cancers has contributed to encouraging outcomes in preclinical models over decades, thus recent clinical trials have investigated its therapeutic application in counteracting pancreatic cancer cells. 47 Programmed cell death receptor ligand (PD1/PDL1)-inhibitors seem to be a promising therapeutic approach in a number of human cancers, as well as in pancreatic cancer, enhancing the anti-tumor immune response in PDL1-upregulated tumors in preclinical models. 48 Birnbaum et al. 48 analyzed PDL1 mRNA expression in 453 pancreatic cancer samples and demonstrated that PDL1 upregulation was observed in 19% of cancer samples, compared to normal samples, leading to shorter disease-free survival and overall survival rates. In a multicenter phase I trial, a total of 207 patients with selected advanced cancers, received intravenous anti-PDL1 antibody. 49 Response rates were ranged from 6% to 17% of all patients and disease stabilization was extended in patients with advanced cancers, including non-small-cell cancer, melanoma, renal-cell cancer and ovarian cancer, but not in patients with pancreatic cancer. 49 Additional clinical trials are needed to evaluate efficacy and safety of PDL1 inhibitors specifically in patients with advanced pancreatic cancer.
CTLA-4 (CD152) is another checkpoint receptor target
for immunotherapy in pancreatic cancer, which controls early stages of T-cell activation. 47 Preclinical models presented improved tumor local control and its decrease after utilization of the anti-CTLA-4 agent, ipilimumab. 47 Le et al. 
VASCULAR RESECTIONS
Historically, arterial abutment has been considered as a contraindication to pancreatectomy (PD), due to increased perioperative morbidity and mortality specially related to arterial resection and reconstruction, compared to standard PD. months from surgery. 52 Moreover, an ongoing multicenter phase II clinical trial (JASPAC05) is about to evaluate neoadjuvant S-1 with concurrent radiotherapy as preoperative treatment for patients with borderline resectable pancreatic tumors occluding major vessels. 53 The primary objective of the study is R0 resection rate, while the secondary endpoints include safety of systematic treatment and subsequent surgery, survival rates, response rates to treatment and pathological response rate. 53 Fujii et al. 54 pub- Nevertheless, in selected cases, such as young age and high radiological and biological response to systemic therapy, combined arterial resection with PD should be taken into account as the best treatment option resulting in potential locoregional control and increased survival rates. 52, 54 Generally, thanks to novel perioperative management techniques and multidisciplinary systemic treatment, concomitant venous and arterial resection and reconstruction have thus been aggressively attempted in combination with significantly higher negative resection margins and disease-free survival rates versus upfront vascular resection and adjuvant chemoradiation therapy. 1 has not found to be significantly different between resectable and advanced tumor patients. 58 Consequently, nearly one-third of tumors initially deemed marginal for operative intervention were eventually able to be resected following neoadjuvant treatment.
